The federal government’s stores of a key Covid-19 antibody drug, a crucial weapon for keeping the infected out of the hospital, are expected to be used up in late August because pandemic funding is running out.
Biden administration officials have told Congress that the government’s supply of the Eli Lilly & Co. therapy, the only antibody drug for treating nonhospitalized patients that was found to work against Omicron, could run out if pandemic funding isn’t renewed. The supply could be depleted before fall if the pace of current use holds.
